Roche’s antibody cocktail for Covid rolls out in India
May 24, 2021
Price to a patient, including tax, is ₹59,750
Doctors treating Covid-19 patients will now also have the antibody cocktail – Casirivimab and Imdevimab – for treatment. The first batch of the injectable from Swiss drugmaker Roche has been imported to India from the US, and the second batch is expected by mid-June. Cipla will market the product in India.
Global attention
The antibody cocktail received much global attention last year after former US President Trump was given the drugwhen he had contracted Covid.
A total of one lakh packs are slated for India, but each pack can treat two patients, said the company. The price to a patient is ₹59,750, inclusive of taxes, said the company, with the two-dose pack costing ₹119,500.
Roche s antibody cocktail drug will be available through leading hospitals and Covid treatment centers.
NEW DELHI: Drug major Roche India on Monday announced the launch of its first batch of antibody cocktail against Coronavirus in India. The antibody cocktail (Casirivimab and Imdevimab)is priced at Rs 59,750 per dose and will be marketed by Cipla in the country.
The Roche s antibody cocktail was given to then US President Donald Trump when he contracted the coronavirus disease in October last year. The first batch of the antibody cocktail (Casirivimab and Imdevimab) is now available in India while a second batch will be made available by mid-June. In total they can potentially benefit 2,00,000 patients as each of the 1,00,000 packs that will be available in India offers treatment for two patients, Cipla and Roche said in a joint statement.
May 19, 2021 5:00pm
Roche s Tecentriq cut the risk of post-surgery cancer recurrence or death by 34% against best supportive care in patients with PD-L1-postivie stage II to IIIA non-small cell lung cancer. (Roche)
In early cancer that’s amenable to surgery, a field viewed as the next battleground for PD-1/L1 immunotherapies, Roche’s Tecentriq has claimed the first win in non-small cell lung cancer. But the drug’s role, at least in some patients, remains unclear.
Tecentriq slashed the risk of cancer recurrence or death after surgery by 34% in a study slated for the virtual American Society of Clinical Oncology meeting next month but only in patients with stage II to IIIA disease whose tumors bore the PD-L1 biomarker.
Roche’s Spark Therapeutics and fellow biotech bluebird bio are both developing gene therapies for blood disorders. Now, the two have found themselves in a legal battle that’s not about their treatments but trademarks.
Roche receives FDA authorisation for testing of asymptomatic people with the cobas SARS-CoV-2 Test to help control the spread of COVID-19
The high-throughput, highly sensitive cobas SARS-CoV-2 Test under FDA Emergency Use Authorisation can now be used to test individual or pooled samples from people without symptoms or other reasons to suspect COVID-19
Accurate, reliable and early detection of SARS-CoV-2 in potentially exposed individuals can help limit the spread of disease
PLEASANTON, Calif., May 18, 2021 /PRNewswire/ Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that its
cobas SARS-CoV-2 Test for use on the widely available, high-throughput
cobas 6800/8800 Systems has received Emergency Use Authorisation (EUA) from the U.S. Food and Drug Administration (FDA) for testing individuals without symptoms or reasons to suspect COVID-19. This authorisation supports the guidance update from the U.S. Centers for Disease Control and Prevention (CDC) to expand SARS-CoV